Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

2 years ago

Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential…

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

2 years ago

Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11%…

Surgalign™ Announces the First Successful Surgical Procedure Utilizing its HOLO Portal™ Surgical Guidance System

2 years ago

Indiana Spine Hospital is the first to utilize the HOLO Portal system, the world’s first artificial intelligence (AI) and augmented…

Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022

2 years ago

Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life…

Pure Extracts Provides Q2 Corporate Update

2 years ago

VANCOUVER, British Columbia, May 05, 2022 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure…

Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

2 years ago

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

Coherus BioSciences Appoints Charlie Newton to Board of Directors

2 years ago

- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus’ immuno-oncology…

Smart for Life Names Darren C. Minton Chief Executive Officer

2 years ago

Mr. Minton Has Served as President Since 2017 Darren C. Minton Chief Executive OfficerMIAMI, May 05, 2022 (GLOBE NEWSWIRE) --…

Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

2 years ago

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to…

Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education

2 years ago

Live Demonstration of New RhodoLED® XL to be Featured WOBURN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:…